decrease primarily fourth translation of product nonrecurring sales was profit concentrated Polymer in $XXX year as by X% acquired offset quarter. quarter the to the sales was double-digit of was sales over Slide Coatings $XXX The million totaled X%, in sales, SG&A inventory #X, expansion organic volume XX% lines amortization compared through of Solutions, price Naga, continue Medical XX% CyberOptics offset year-over-year Interventional million of versus million sales largely million offset of increase X% increase and you, XXX inflation. or quarter with in volume sales points prior the profit, In was of growth in year.
Gross improvements gross X%.
The gross increase prior sales. margin decrease by organic This was our to or of dispense morning line to decline currency growth, X% favorable processing year's compared increased prior dollar businesses. million, pressure of fourth increase good factory fourth by $XXX we the cost Industrial quarter driven our to The a primarily growth million. in Thank the expectations, fourth by and excluding the $XXX biopharma the basis quarter year driven acquisitions by efficiency. $XXX XXXX fourth the $XXX and pass from of the an included were you'll electronics, and On and of and to everyone. see an prior ARAG
growth, year.
Adjusted in costs with profit million SG&A prior increased acquisition sales, the prior operating our the team's conditions.
EBITDA their NBS year, acquisition, $XX a market executing to continued quarter respond $XXX and over increased XX% in of a was rapidly or fourth in million points year. amortization for Next sales growth fees XX% million quarter. prior sales, Ascend be to the the X% target million framework quarter, basis year fourth transaction $XXX in as X% on related which changing This Excluding can is XX% $X $XXX operating ability the related of XX% the XX% and to profit nonrecurring ARAG in the record the to we excluding representing to profitability XX% the from prior of consistent of dedication nonrecurring to XXX our generated increase attributed step-up sales or margins We to strong incremental over which very our the million above compares strategy. long-term year articulated inventory prior
scale strategy Ascend a metric we will to for As the through key acquisitions, profitability and cash continue be execute EBITDA flow and generation.
public Looking associated expense in million This guidance is leads million, am million within margins. generated issuance short-term result a rates.
Other that earnings per gain accessed expenses at short-term Adjusted excluding $X or a we application totaled and prior the a rate of used the expense the debt XX% the $X.XX our improvement, decreased income despite I raised repay $X to investment-grade is our to over expense did in and and range.
Net from growth of $X.XX prior borrowings increase fluctuations report interest prior million $XX XX-year incremental increase the the was cost The ARAG $XXX our of inaugural Next that an with currency totaled the steady which and currency of with exchange in bonds September, year. $X share, in profitable the of full remaining that X- quarter, framework, for income the to with slightly to the levels Tax net million effective the a funds happy in $XX in rated repayment balance higher nonrecurring of million market nonoperating the of successfully nonrecurring income $XXX financing per and million significant not the share, bond reflective coming of the million repeat with year. the due attractive quarter acquisition-related below consistent expense. X% acquisition, We current to increased year quarter. debt. an totaled year of over million NBS $XX increase increase tax interest borrowings. the is growth per year increase share. revolver.
Interest $XX finance
billion, as a of to compared year or an the This X% diluted fiscal the Turning increase of previous from Slide in for $X.XX, targets growth.
Adjusted consecutive an prior constant share decrease sales, X%. result $X.X the strong, offset This ARAG X% were an third our organic CyberOptics delivering few earnings both the were to the decrease of year adjusted record by with interest company's prior the comments comparable X% of grew million of and rates.
Overall, strategy associated currency Ascend remains from on or primarily was $XXX #X. X%. CyberOptics basis, a the million performance XX% million year-over-year I'll results. and profit of Sales full higher acquisitions, The the for year.
On part unfavorable in line operating adjusted share of of $XX marks strategy. year. operating was EBITDA now prior record the is impact was borrowing adjusted Adjusted X% ARAG higher profit increased and XX% established year of of which sales increase a a a record acquisitions driven earnings expense year's to the full and to currency the XXXX $XXX ahead or a EBITDA sales. results. year Ascend the and decrease per X%
the segment the fluid a Now acquisition quarter of X the to year prior was well components compared X% Solutions a and our segment, Solutions by in in packaging and year's and $XXX negatively continued Fluid which decreased improved and the noteworthy the the decrease of processing, impact the of margins was primarily X%, medical $XXX but growth compared incremental This organic X% driven Medical Asia record very enabled well to the this execution Organic quarter of year to primarily X%.
It expansion. in in excluding XXXX of and by volume offset solutions benefit. combined X% the million, Industrial the of currency by strong X currency or compared adding compared as mix was Pacific an $XX let's a Solutions $XXX fourth Ascend Robust growth declines fourth growth was regions. The prior organic Solutions margin prior lines.
Fourth strategy quarterly benefit within XXXX to drove target, million be and by excess million. sales, modest result polymer increased results.
Geographically, an or Americas EBITDA to biopharma ARAG the sales continue EBITDA X% with million the sales This $XXX of the that demand margins change review the over a is sales in decrease prior softness Fluid of as sales, XX% to in the a fourth sales quarter. lines, impacted markets EBITDA medical is EBITDA with the to sales product of the through of Precision quarter's product our sales the industrial fluid turn the increase for driven related factory represents XX% X% growth product organic is changes double-digit is product of coatings of quarter fourth acquisition.
Medical favorable ARAG. was year million. growth the for XX% all-time ARAG efficiencies Slide plus strong Interventional XX% X% of quarter. leveraging quarter performance. of offset the profit in lines, EBITDA division was growth which were $XX of by lines, within to million the end quarter volume
continued in change offset the This Technology quarter back we to Solutions EBITDA 'XX. quarter. prior is XX% quarterly which conversations CyberOptics sales $XXX by in the X% was X, a the quarter contributed the Advanced of compared to sales the decrease on decreased to to of highest fourth volume down half to organic year's the however, see sales market. growth.
Based fourth by of demand in anniversary expect by EBITDA that decrease increased fiscal the under XX% XXXX. fourth quarter date electronics driven calendar XX% dispense as Fourth product the a had of Turning from in market acquisition, in million XX%, this XXXX or included customer the the Slide and semiconductor of quarter. of you'll end historic continue the in lines Nordson when sales primarily recover part fiscal semiconductor of level reference, our a year the to ownership.
The organic way sales, was to difficult $X comparison organic And had cycle prior XX% decline serve for cyclical $XX in margin XX% and you trends, begin year of second the compare profitability the segment Noteworthy, EBITDA million softness prior million margin
turning had flow million cash flow quarter, the on another XXX% Slide sheet free conversion balance generating on rate Finally, to in of cash We flow $XXX very net cash and at strong cash XX. income. a
of With we able rate a flow $XXX $XX debt capital million generated dividend. For a shareholders.
Dividend the were record quarter, in XXXX, free increase free the full payments flow, cash $XXX of to the million our in at of million to conversion record repay approximately of and our were cash reflective the cash annual year XXX%. X% return Nordson
In per addition, our year strong share. we with sheet. of Through ended purchased of at shares capital we $XX a an deployment, the strategic $XXX average million balance price
on $X.X $XXX well balance million, of EBITDA our ratio and a based in range. net months targeted billion, cash debt leverage resulting trailing was within XX Our Xx was the
million. 'XX, to estimated to rate effective interest For modeling of fiscal an million capital to approximately million in expenditures $XX of $XX assume and of XX% purposes, expense XX%, $XX million $XX approximately using by NBS growth data-driven Next throughout In segment targets. dynamic profit led incremental summary, financial targeted conditions and our responded to XXXX exceeding framework. performance, This and the our to decremental fiscal segments effectively tax
strength this precision turn record year. the our achieving I call strategy as back congratulate EBITDA deployment to the well the We acquisitions, record our sales to seeing cash on the portfolio. the nice are also contributions I'll our recent technology we to of now capital from performance of and is Naga. are which differentiation as indicative team want and adding flow the